Chemical Properties
| storage temp. | Store at 4°C,Do not freeze |
| solubility | Soluble in DMSO |
| form | Liquid |
| color | Colorless to light yellow |
reslizumab Chemical Properties,Usage,Production
Uses
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].Clinical Use
Treatment of severe eosinophilic asthmain vivo
Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice[3].
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3].
| Animal Model: | Male B6D2F1/J mice weighing 2025 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3] |
| Dosage: | 010 mg/kg |
| Administration: | Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.) |
| Result: | Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463). |
Drug interactions
Potentially hazardous interactions with other drugsVaccines: risk of generalised infections with live vaccines - avoid.
IC 50
IL-5: 91.1 pM (IC50)Metabolism
Reslizumab is believed to be degraded by enzymatic proteolysis into small peptides and amino acids. As reslizumab binds to a soluble target, linear non-targetmediated clearance is expected.References
[1] Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. DOI:10.4168/aair.2019.11.2.291[2] Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. DOI:10.1111/all.14035
[3] Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90. DOI:10.1055/s-0031-1300502
reslizumab Suppliers
Global(31)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | 7353 | 58 | ||
| 16314854226 | info@bocsci.com | 0 | 65 | ||
| 15111215862 18229892877 | 3062105966@qq.com | 5580 | 58 | ||
| 18024082417 | market@ubiochem.com | 9831 | 58 | ||
| +86-02787215551 19945035818 | 2936752263@qq.com | 7937 | 58 | ||
| 15817493340 | 981810490@qq.com | 1577 | 58 | ||
| 027-65279366 18108604356 | products@biolabreagent.com | 9864 | 58 | ||
| 17316404525 17316404525 | 209533805@qq.com | 9790 | 58 | ||
| 021-65675885 18964387627 | customer_service@efebio.com | 11963 | 58 |